BioSpace News Archive

Fact.MR, Rockville MD: Award winning market research company Fact.MR’s ongoing study on the bed headwall systems market projects a largely positive forecast for 2021.

The global electrophysiology ablation market is projected to witness an upsurge in demand with increasing prevalence of atrial fibrillation and arrhythmia.

The use of cannabidiol is increasing at a rapid rate over the years. Cannabidiol is a widely used type out of all cannabinoids.

The co-chairs of the federal, provincial and territorial Special Advisory Committee on the Epidemic of Opioid Overdoses—Dr. Theresa Tam, Canada’s Chief Public Health Officer and Dr. Jennifer Russell, New Brunswick’s Chief Medical Officer of Health—issued the following statement on the release of updated data on opioid- and stimulant-related harms in Canada, covering the period of January 1, 2016 to September 30, 2020.

TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the fourth quarter and full year ended December 31, 2020. Recent Highlights

Fourth patient treated in pivotal Phase 3 VIITAL™ study of EB-101 in RDEB after successful Type B meeting with FDA Positive new interim data from MPS IIIA and MPS IIIB programs presented at 17 th Annual WORLDSymposium

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the quarter and full year ended December 31, 2020.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Stephanie Lovell to its Board of Directors and as a member of the Nominating and Corporate Governance Committee, effective March 22, 2021.

Fourth Quarter Results Significantly Impacted by Weak Cough, Cold and Flu Season, Continued Effects Related to the COVID-19 Pandemic and Difficult Weather Conditions

Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted fourteen new employees options to purchase a total of 157,300 shares of the Company’s common stock at an exercise price per share of $34.45, which was the closing price on March 23, 2021.